Loading stock data…
AstraZeneca PLC (AZN)
$169.26+0.99 (+0.59%)
After Hours$168.11-1.15 (-0.68%)· Last close Jul 24
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AstraZeneca PLC in the Healthcare sector is trading at $169.26 with a market capitalization of $276.4B. Wall Street consensus targets $213.89 (10 analysts), implying a +26.4% move over the next 12 months. The stock is currently 20% below its 52-week high of $212.71, remaining 8.0% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +26.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.29B↓ | $15.50B↑ | $15.19B↑ | $14.46B↑ | $13.59B |
| Gross Profit | $12.61B↑ | $12.38B | $12.39B↑ | $11.98B↑ | $11.35B |
| Operating Income | $4.25B↑ | $2.98B↓ | $3.58B↑ | $3.51B↓ | $3.67B |
| Net Income | $3.08B↑ | $2.33B↓ | $2.53B↑ | $2.45B↓ | $2.92B |
Peer Comparison
JNJUNHPFE
Fundamentals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$276.38B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.88%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.95%
Volume
Today's trading volume
2.01M
Recent News
AstraZeneca (LSE:AZN) Wins EU Approval For Etcamah In Advanced Breast Cancer
AstraZeneca received EU approval for Etcamah (camizestrant) in combination with CDK4/6 inhibitors for ER-positive, HER2-negative advanced breast cancer. The decision is based on Phase III SERENA-6 trial results in patients with emerging endocrine resistance. The new regimen targets a major breast cancer subtype and expands AstraZeneca's approved oncology treatments in Europe. AstraZeneca, traded as LSE:AZN, now has regulatory backing in the EU for Etcamah in combination with CDK4/6...
EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer
AstraZeneca secures EU approval for Etcamah in combination with a CDK4/6 inhibitor for first-line treatment of advanced ER-positive breast cancer patients.
J&J's Innovative Medicine Unit Proves Its Resilience in Q2
JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative
AstraZeneca (LSE:AZN) has been in focus after Illumina highlighted progress on the Billion Cell Atlas alliance. AstraZeneca is a founding member of this initiative, which uses large scale genomic and CRISPR data to support future drug discovery. See our latest analysis for AstraZeneca. Despite AstraZeneca's participation in the Billion Cell Atlas and the new Zegfrovy licensing deal, the 30 day share price return is down 6.64% and the 90 day share price return is down 9.09%, while the 1 year...